🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

What do we need to know about an individual to care for & work with them effectively? #AGITG23

The prognosis for brain tumours has always been difficult to define. Today, @HaoWenSim & Ned McNamee present research at SNO on how comprehensive genomic profiling can assist in this astrocytoma prognostication. Subo Garvan Institute of Medical Research @SVHSydney #OncTwitter

seek.com.au/job/71555508 Job opportunity! looking for an oncology haematology career medical officer to join SVPH - inpatient and outpatient (ambulantory care) duties - balanced workload and no on call - enquire within! @SVHSydney ONCODOC has been

Thrilled to lead this exciting project deciphering young-onset colorectal cancer alongside Megan Barnet @KylieReneeJames and Dr Subo Thavaneswaran 🥳

Great summary from Ryan Corcoran Mass General Cancer Center re targeting RAS. Similar single agent ORR G12Cinh PDAC compared w/ NSCLC, vs CRC which improves w/ addition anti-EGFR. Supports KRAS good target in PDAC …just need to progress in G12D #ESMOGI24

Further consideration of ESOPEC w Ian Chau - FLOT in Germany > FLOT rest-of-world? pCR FLOT4, DANTE, ESOPEC 15-17% vs others ~7% #ESMOGI24

Masterclass in ctDNA from Jeanne Tie at #ESMOGI24. Efforts to improve sensitivity inc: track more muts (WES vs panel), reduce BG noise (seq PBMCs, technical improvements), increase cf DNA input (how much blood ethically ok w serial collections) #aussiesonthepodium

A reminder from Prof Karin Haustermans of why rad oncs dislike PROSPECT (…aside from inclusion of patients who didn’t need NA tx) #ESMOGI24

RV of rationale for differing OS + ongoing pref up-front surgery Asian v Western gastric w/ Prof Sun Young Rha Yonsei University: 5yOS >60 v 25% ! Screening program/more early disease, long-standing D2 dissection SoC, diff histo path (non-cardia > cardia). #ESMOGI24

Unsurprising QoL data for TRANSMET, late deviation in favour LT+C v C. Interesting summary from Chiara Cremolini re pattern of relapse liver TP (lung dominant) v resection (liver dominant) #ESMOGI24

KN585 OS (noting EFS/trial stat. neg despite 20m improvement) OS benefit 6% at5yrs. FLOT (v CF) backbone did better (cis poor PD1 partner), but only 20% cohort, clear benefit CPS >10/MSI-H. Appealing option; may solidify w MATTERHORN survival (100% FLOT) Kohei shitara #ESMOGI24

Thought provoking talk from Prof. Irit Ben-Aharon on QoL issues in EOCRC, esp paucity of data re: fertility pres. w/ RT + oxali (can’t extrapolate GnRHa from CTX - can worsen problem), cardiovascular tox (CVD 54% CRC survivors v 17% Gen pop), psychosocial, body image, sexual fnc #ESMOGI24

Laurence Zitvogel Gustave Roussy tour de force microbiome. Meta-anal. AB use -60 to +42d C1 PD1; surge pathogenic bact. post AB down-reg gut checkpoint MadCAM —> exodus immunosupp cells inc Th17 from gut to cancer. PD1 at this point amplifies exodus 🪨/doc/hard place #ESMOGI24

PDAC has more negative trials than any other tumour stream… Trying to find Prof Thomas Seufferlein’s summary slide motivating rather than deflating. Nal-iri combos underwhelming and not compared to FOLFIRI/mFFX #ESMOGI24

Biological rationale of EGFR-MET Bispec Ab Amivantamab w/ Josep Tabernero; averting met-amplification rel. resistance, inducing ADCC. We will test in 1L Ph3 ORIGAMI-2 trial w/ platinum doublet vs CT/cetux in RAS/BRAFwt L-sided mCRC opening soon👊 The Kinghorn Cancer Centre #ESMOGI24

Summary ongoing BRAFm mCRC trials w/ Dominik Paul Modest 1L BREAKWATER MSS Ph3 enco/cetux +/CT v CT-bev 1L SEAMARK MSI Ph2 enco/cetux/pembro v pembro 2L SWOG2107 MSS Ph2 enco/cetux v enco/cetux/nivo 3L BRICKET (🦗) Ph2 rechallenge enco/cetux if no alt ctDNA #ESMOGI24

Promising ORR 32% in CLDN18.2 mod/high (90% cohort) heavily pre treated pt w/ G/GOJ. Similar responses, less N/V than other CLDN18.2 Abs Jia (Jenny) Liu MD PhD The Kinghorn Cancer Centre #ESMOGI24

TOPAZ-1 update at mFU 41m - OS HR strengthened 0.8 —> 0.74, if have a CR/PR 1/3 alive at 3y vs 16% chemo. 17% ‘long term’ survivors, across all subgroups iCCA/eCCA/GBC/ROW/PDL1 #ESMOGI24

Heading home to my very own #messehaus. Thanks #ESMOGI24 Teresa Macarulla @DucreuxMichel and Prof Eric Van Cutsem for a fantastic program and amazing week in Munich! Jia (Jenny) Liu MD PhD The Kinghorn Cancer Centre

Memorable eve at the Lachlan Kean Foundation Ball raising awareness for early onset colorectal cancer Garvan Institute of Medical Research The Kinghorn Cancer Centre GI Cancer Institute and AGITG Bowel cancer screening now starts age 45 or 40 if you ask your GP. Pay attention to symptoms at any age - this disease is changing